Posted on 2/15/18
Ra Pharmaceuticals Prices Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (NASDAQ: RARX) (“Ra Pharma”) today announced the pricing of an underwritten public offering of 8,400,000 shares of its common stock at . . .
Posted on 2/14/18
Is Now a Good Time to Buy Vertex Pharmaceuticals?
Demand for Vertex Pharmaceuticals' (NASDAQ:VRTX) cystic fibrosis drugs is growing rapidly, and that's fueling rapid bottom-line growth, yet Vertex Pharmaceuticals' shares are dropping. Is now a . . .
Posted on 2/13/18
Ra Pharmaceuticals Proposes Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that it intends to offer and sell, subject to market and other conditions, $50 million of its common . . .
Posted on 2/13/18
Abiomed Receives Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic Shock
DANVERS, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has . . .
Posted on 2/13/18
BioXcel Therapeutics Files Registration Statement for Proposed Initial Public Offering
BRANFORD, Conn., Feb. 13, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave . . .
Posted on 2/13/18
Parkview Contracts With BridgeHead to Manage Backup Environment
WOBURN, Mass. and ASHTEAD, United Kingdom, Feb. 13, 2018 (GLOBE NEWSWIRE) -- BridgeHead Software, a leader in healthcare data management, today announced that Parkview Medical Center, . . .
Posted on 2/12/18
Akebia Therapeutics Provides Update on Vadadustat Development Program
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), . . .
Posted on 2/12/18
Concert Pharmaceuticals Progress in CTP-543 Phase 2a Trial for Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated enrollment of the second cohort of its Phase 2a clinical trial evaluating CTP-543. Concert is . . .
Posted on 2/11/18
Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration
BOSTON & BOTHELL, Wash.--(BUSINESS WIRE)--Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and . . .
Posted on 2/9/18
Cerveau Technologies Signs Research Agreement with Massachusetts General Hospital
BOSTON--(BUSINESS WIRE)--Cerveau Technologies Inc. today announced an agreement with Massachusetts General Hospital (MGH) to support multiple projects over the next several years. These research projects are . . .
Posted on 2/8/18
Syros Closes Public Offering and Full Exercise of Option to Purchase Additional Shares
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced the closing of its . . .
Posted on 2/8/18
Sage Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has . . .
Posted on 2/7/18
3 Megacompanies Want to Shake Up Healthcare
When it comes to sky-high healthcare costs, Amazon.com (NASDAQ:AMZN), Berkshire Hathaway (NYSE:BRK-A)(NYSE:BRK-B), and JPMorgan Chase (NYSE:JPM) have had enough. The three companies are creating a new . . .
Posted on 2/6/18
Sysmex America Expands Use of ThingWorx Platform to Transform the Patient Experience
NEEDHAM, Mass.--(BUSINESS WIRE)--PTC (NASDAQ: PTC) and Sysmex America today announced that Sysmex has expanded its use of the ThingWorx® Industrial Innovation Platform to enable Sysmex to . . .
Posted on 2/6/18
3 Things to Really Like About Bristol-Myers Squibb's Q4 Earnings Results
When Bristol-Myers Squibb (NYSE:BMY) reported its third-quarter earnings results in October, some investors might have wondered if they needed to worry. The big pharma company posted . . .
Posted on 2/5/18
Boston Scientific Corporation 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Boston Scientific Corporation in conjunction with their 2017 Q4 earnings call. 129READ FULL ARTICLE HERE
Posted on 2/5/18
Berkshire Hathaway: Looking Beyond Net Earnings
IntroductionMy thesis is that we have to look beyond net earnings to understand the economics of Berkshire Hathaway (BRK.A, BRK.B). I look at book value as . . .
Posted on 2/5/18
Athenahealth, Inc. Returns to Stronger Growth in Fourth Quarter
Things looked somewhat gloomy the last time athenahealth, Inc. (NASDAQ:ATHN) provided a quarterly update. In October, the cloud-based healthcare applications provider reported a deteriorating bottom line, . . .
Posted on 2/5/18
Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BURLINGTON, Mass., Feb. 02, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to six new employees for an . . .
Posted on 2/2/18
athenahealth's (ATHN) CEO Jonathan Bush on Q4 2017 Results - Earnings Call Transcript
Good morning, and thank you for joining us. With me on the call today is Jonathan Bush, our Chief Executive Officer; and Marc Levine, our Chief . . .
Posted on 2/2/18
Boston Scientific's (BSX) CEO Michael Mahoney on Q4 2017 Results - Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX) Q4 2017 Earnings Conference Call February 1, 2018 7:30 AM ETExecutivesSusan Lisa - Vice President of Investor Relations, Boston ScientificMichael Mahoney - . . .
Posted on 2/2/18
Thermo Fisher Scientific Inc. 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Thermo Fisher Scientific Inc. in conjunction with their 2017 Q4 earnings call. 114READ FULL ARTICLE HERE
Posted on 2/2/18
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of . . .
Posted on 2/1/18
Biogen: Numbers Are Fine But Valuation Isn't Appealing
On January 25, 2018, Biogen (NASDAQ:BIIB) reported strong Q4 2017 results, thanks to a solid performance of Tecfidera and Spinraza and an excellent Opex management.Even if . . .
Posted on 1/31/18
Juniper Pharmaceuticals to Explore Strategic Alternatives
Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a diversified healthcare company focused on women's health, today announced that it is exploring strategic alternatives in order to enhance shareholder value. . . .

